Your browser doesn't support javascript.
loading
Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39.
Bassilana, Frederic; Carlson, Adam; DaSilva, Jennifer A; Grosshans, Bianka; Vidal, Solange; Beck, Valerie; Wilmeringwetter, Barbara; Llamas, Luis A; Showalter, Todd B; Rigollier, Pascal; Bourret, Aaron; Ramamurthy, Arun; Wu, Xu; Harbinski, Fred; Plonsky, Samantha; Lee, Lac; Ruffner, Heinz; Grandi, Paola; Schirle, Markus; Jenkins, Jeremy; Sailer, Andreas W; Bouwmeester, Tewis; Porter, Jeffrey A; Myer, Vic; Finan, Peter M; Tallarico, John A; Kelleher, Joseph F; Seuwen, Klaus; Jain, Rishi K; Luchansky, Sarah J.
Afiliação
  • Bassilana F; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Carlson A; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • DaSilva JA; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Grosshans B; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Vidal S; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Beck V; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Wilmeringwetter B; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Llamas LA; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Showalter TB; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Rigollier P; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Bourret A; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Ramamurthy A; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Wu X; 1] Genomics Institute of the Novartis Research Foundation, San Diego, California, USA. [2].
  • Harbinski F; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Plonsky S; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Lee L; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Ruffner H; 1] Cellzome AG, Heidelberg, Germany. [2].
  • Grandi P; Cellzome AG, Heidelberg, Germany.
  • Schirle M; 1] Cellzome AG, Heidelberg, Germany. [2].
  • Jenkins J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Sailer AW; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Bouwmeester T; 1] Cellzome AG, Heidelberg, Germany. [2].
  • Porter JA; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Myer V; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Finan PM; 1] Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA. [2].
  • Tallarico JA; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Kelleher JF; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Seuwen K; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Jain RK; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Luchansky SJ; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Nat Chem Biol ; 10(5): 343-9, 2014 May.
Article em En | MEDLINE | ID: mdl-24633354
ABSTRACT
Hedgehog (Hh) signaling determines cell fate during development and can drive tumorigenesis. We performed a screen for new compounds that can impinge on Hh signaling downstream of Smoothened (Smo). A series of cyclohexyl-methyl aminopyrimidine chemotype compounds ('CMAPs') were identified that could block pathway signaling in a Smo-independent manner. In addition to inhibiting Hh signaling, the compounds generated inositol phosphates through an unknown GPCR. Correlation of GPCR mRNA expression levels with compound activity across cell lines suggested the target to be the orphan receptor GPR39. RNA interference or cDNA overexpression of GPR39 demonstrated that the receptor is necessary for compound activity. We propose a model in which CMAPs activate GPR39, which signals to the Gli transcription factors and blocks signaling. In addition to the discovery of GPR39 as a new target that impinges on Hh signaling, we report on small-molecule modulators of the receptor that will enable in vitro interrogation of GPR39 signaling in different cellular contexts.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Acoplados a Proteínas G / Proteínas Hedgehog Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Acoplados a Proteínas G / Proteínas Hedgehog Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article